# EDGAR Filing Document

**Accession Number:** 0001736243
**File Stem:** 0001104659-25-068659
**Filing Date:** 2025-7
**Character Count:** 8275
**Document Hash:** cbe164bc7d51894f2e6f29ea66ee4824
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-068659.hdr.sgml**: 20250717

**ACCESSION NUMBER**: 0001104659-25-068659

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250717

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250717

**DATE AS OF CHANGE**: 20250717

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Acurx Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001736243
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40536
- **FILM NUMBER:** 251130724

**BUSINESS ADDRESS:**
- **STREET 1:** 259 LIBERTY AVENUE
- **CITY:** STATEN ISLAND
- **STATE:** NY
- **ZIP:** 10305
- **BUSINESS PHONE:** 917-533-1469

**MAIL ADDRESS:**
- **STREET 1:** 259 LIBERTY AVENUE
- **CITY:** STATEN ISLAND
- **STATE:** NY
- **ZIP:** 10305

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Acurx Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20180402

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of The Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** **July 17, 2025**

**Acurx Pharmaceuticals, Inc.** 

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40536** | **82-3733567** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission<br> File Number)** | **(IRS Employer<br> Identification No.)** |

---

**259 Liberty Avenue, Staten Island, NY 10305** 

**(Address of principal executive offices) (Zip Code)** 

**Registrant's telephone number, including area code: (917) 533-1469**

**Not applicable** 

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br> Symbol** | **Name of each exchange<br> on which registered** |
| **Common Stock, par value $0.001 per share** | **ACXP** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

At the close of business on May 27, 2025, the record date of the annual meeting of Acurx Pharmaceuticals, Inc. ("we", "us", "our" and "the Company") held on July 17, 2025 (the "Annual Meeting"), there were 23,481,606 shares of common stock outstanding and entitled to vote. At the Annual Meeting, the holders of 17,467,327 shares of our common stock, or approximately 74.38% of our outstanding shares of common stock, were represented in person or by proxy and, therefore, a quorum was present. At the Annual Meeting, our stockholders considered six proposals, which are described briefly below and in more detail in our definitive Proxy Statement filed with the Securities and Exchange Commission on May 29, 2025. The final voting results for each proposal are set forth below.

**Proposal 1 - Election of Directors**

Our stockholders elected the following directors as Class I directors to hold office until the 2028 annual meeting of stockholders by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Nominees** | **Shares Voted<br> For** | **Shares <br> Withheld** | **Broker <br> Non-Votes** |
| Carl V. Sailer | 8901598 | 2498656 | 6067073 |
| Thomas Harrison | 9569165 | 1831089 | 6067073 |

---

**Proposal 2 - Ratification of Independent Registered Public Accounting Firm**

Our stockholders ratified the appointment of CohnReznick LLP as our independent auditors for the fiscal year ending December 31, 2025, by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted For** | **Shares Voted Against** | **Abstentions** | **Broker Non-Votes** |
| 16381852 | 354692 | 730783 | -- |

---

**Proposal 3 – Approval of Reverse Stock Split**

Our stockholders approved an amendment to our certificate of incorporation to effect a reverse stock split at a ratio not less than 1:10 and not more than 1:30 (the "Reverse Stock Split"), such ratio and the implementation and timing of such Reverse Stock Split to be determined in the discretion of our board of directors by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted For** | **Shares Voted Against** | **Abstentions** | **Broker Non-Votes** |
| 15991274 | 1389599 | 86454 | -- |

---

**Proposal 4 – Approval of Warrant Exercise**

Our stockholders approved, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of common stock underlying (x) series F warrants (the "Series F Warrants") and (y) warrants (the "Wainwright Warrants," and together with the Series F Warrants, the "Warrants") issued to H.C. Wainwright & Co., LLC ("Wainwright"), pursuant to that certain Securities Purchase Agreement, dated March 6, 2025, and the investors named therein, and that certain Engagement Letter, dated as of October 9, 2024, by and between the Company and Wainwright, respectively, in an amount equal to 20% or more of our common stock outstanding before the issuance of such Warrants by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted For** | **Shares Voted Against** | **Abstentions** | **Broker Non-Votes** |
| 10481270 | 811332 | 107652 | 6067073 |

---

**Proposal 5 – Approval of ELOC**

Our stockholders approved, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock to Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to that certain Purchase Agreement, dated May 8, 2025, by and between the Company and Lincoln Park, in an amount equal to 20% or more of our common stock outstanding before the execution of such Purchase Agreement by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted For** | **Shares Voted Against** | **Abstentions** | **Broker Non-Votes** |
| 9825684 | 837947 | 736623 | 6067073 |

---

**Proposal 6 – Approval of 2021 Plan Increase**

Our stockholders approved an amendment to our 2021 Equity Incentive Plan (the "2021 Plan") to increase the number shares of common stock available for sale under the 2021 Plan from 177,448 to 2,677,448 by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted For** | **Shares Voted Against** | **Abstentions** | **Broker Non-Votes** |
| 7627995 | 3036913 | 735346 | 6067073 |

---

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Acurx Pharmaceuticals, Inc. | Acurx Pharmaceuticals, Inc. |
| Date: July 17, 2025 |  |  |
|  | By: | /s/ David P. Luci |
|  | Name: | David P. Luci |
|  | Title: | President and Chief Executive Officer |

---